Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer: A southwest oncology group study

D. D. Von Hoff, S. Green, D. S. Alberts, D. L. Stock-Novack, E. A. Surwit, T. P. Miller, R. L. Stephens

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Nineteen evaluable patients with advanced endometrial cancer refractory to one prior chemotherapeutic regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was grade 2 or greater leukopenia in 45% of patients. Fludarabine phosphate at this dose and schedule does not appear to be an active agent for patients with refractory endometrial cancer.

Original languageEnglish (US)
Pages (from-to)193-194
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number3
DOIs
StatePublished - 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer: A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this